Document Detail


The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report.
MedLine Citation:
PMID:  3071336     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
End-stage renal disease (ESRD) typically is associated with severe anemia. The major contributor to the anemia appears to be the absolute or relative deficiency of erythropoietin (EPO) production by the kidney. A series of clinical trials have been conducted in the United States using recombinant human EPO (rh EPO) to treat anemic patients with ESRD. The encouraging results of the Phase I-II clinical trials have been confirmed in a multicenter trial in which over 250 patients have been treated. The results indicate that rh EPO can effectively correct the anemia of ESRD and the rate of correction is dependent upon the initial dose given. The rHuEpo was well tolerated, produced few or no direct side effects, and was effective in greater than 95 percent of the patients. rh EPO should have a major role in the correction of the anemia of ESRD and contribute significantly to the rehabilitation of such patients.
Authors:
W Adamson; J C Egrie; J K Browne; M R Downing; W Eschbach
Related Documents :
16512996 - Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine deh...
12038516 - Upper and lower gastrointestinal endoscopical investigation in elderly patients with ir...
17610536 - Myocardial iron loading by magnetic resonance imaging t2* in good prognostic myelodyspl...
2926086 - Long-term prophylaxis with c1-inhibitor (c1 inh) concentrate in patients with recurrent...
2484906 - Low thyrotropin (tsh) levels in goiter. relationship with scintigraphic findings and ot...
20944536 - Overactive bladder syndrome: what is the role of evidence of detrusor overactivity in t...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Behring Institute Mitteilungen     Volume:  -     ISSN:  0301-0457     ISO Abbreviation:  Behring Inst. Mitt.     Publication Date:  1988 Aug 
Date Detail:
Created Date:  1989-04-26     Completed Date:  1989-04-26     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0367532     Medline TA:  Behring Inst Mitt     Country:  GERMANY, WEST    
Other Details:
Languages:  eng     Pagination:  188-92     Citation Subset:  IM    
Affiliation:
Department of Medicine, University of Washington, Seattle.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anemia / drug therapy*,  etiology
Clinical Trials as Topic
Erythropoietin / adverse effects,  therapeutic use*
Ferritins / blood
Hematocrit
Humans
Kidney Failure, Chronic / blood*
Recombinant Proteins / adverse effects,  therapeutic use*
Grant Support
ID/Acronym/Agency:
DK 19410/DK/NIDDK NIH HHS; DK 33488/DK/NIDDK NIH HHS; FR 0037//PHS HHS
Chemical
Reg. No./Substance:
0/Recombinant Proteins; 11096-26-7/Erythropoietin; 9007-73-2/Ferritins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Recombinant granulocyte/macrophage-colony stimulating factor in human and murine bone marrow transpl...
Next Document:  Human recombinant derived IL-3 and GM-CSF in hematopoiesis of normal cynomolgus monkeys.